Retorno sobre el índice de capital contable (ROE)
desde 2005
Bajo nivel de dificultad
Cálculo
Bristol-Myers Squibb Co., ROE, tendencias a largo plazo, cálculo
| ROE | = | 100 | × | Utilidad (pérdida) neta atribuible a BMS1 | ÷ | Capital contable total de Bristol-Myers Squibb Company1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | -23.84% | = | 100 | × | (9,015) | ÷ | 37,822 |
| 31 dic. 2019 | 6.66% | = | 100 | × | 3,439 | ÷ | 51,598 |
| 31 dic. 2018 | 35.07% | = | 100 | × | 4,920 | ÷ | 14,031 |
| 31 dic. 2017 | 8.58% | = | 100 | × | 1,007 | ÷ | 11,741 |
| 31 dic. 2016 | 27.55% | = | 100 | × | 4,457 | ÷ | 16,177 |
| 31 dic. 2015 | 10.97% | = | 100 | × | 1,565 | ÷ | 14,266 |
| 31 dic. 2014 | 13.49% | = | 100 | × | 2,004 | ÷ | 14,852 |
| 31 dic. 2013 | 16.91% | = | 100 | × | 2,563 | ÷ | 15,154 |
| 31 dic. 2012 | 14.39% | = | 100 | × | 1,960 | ÷ | 13,623 |
| 31 dic. 2011 | 23.25% | = | 100 | × | 3,709 | ÷ | 15,956 |
| 31 dic. 2010 | 19.74% | = | 100 | × | 3,102 | ÷ | 15,713 |
| 31 dic. 2009 | 71.49% | = | 100 | × | 10,612 | ÷ | 14,843 |
| 31 dic. 2008 | 42.86% | = | 100 | × | 5,247 | ÷ | 12,241 |
| 31 dic. 2007 | 20.50% | = | 100 | × | 2,165 | ÷ | 10,562 |
| 31 dic. 2006 | 15.86% | = | 100 | × | 1,585 | ÷ | 9,991 |
| 31 dic. 2005 | 26.77% | = | 100 | × | 3,000 | ÷ | 11,208 |
Fuente: Bristol-Myers Squibb Co. (NYSE:BMY) | Return on Equity since 2005 (www.stock-analysis-on.net)
1 US $ en millones
Comparación con la competencia
Bristol-Myers Squibb Co., ROE, tendencias a largo plazo, comparación con la competencia
| Bristol-Myers Squibb Co. | Abbott Laboratories | AbbVie Inc. | Amgen Inc. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | -23.84% | 13.71% | 35.30% | 77.20% | 109.79% | 0.68% | 13.98% | 23.25% | 27.91% | 15.21% | 31.86% | 31.22% | 43.46% |
| 31 dic. 2019 | 6.66% | 11.86% | — | 81.07% | 319.09% | 23.91% | 21.72% | 25.42% | 37.99% | 25.77% | 19.08% | 19.34% | 55.39% |
| 31 dic. 2018 | 35.07% | 7.76% | — | 67.15% | 32.88% | 25.51% | 21.98% | 25.60% | 23.30% | 17.59% | 27.91% | 47.28% | 65.35% |
| 31 dic. 2017 | 8.58% | 1.54% | 104.16% | 7.84% | -1.76% | 22.64% | 26.41% | 2.16% | 6.97% | 29.47% | 19.51% | 12.99% | 48.81% |
| 31 dic. 2016 | 27.55% | 6.82% | 128.41% | 25.85% | 19.54% | 71.48% | 21.06% | 23.49% | 9.78% | 12.12% | 20.13% | -9.69% | 55.21% |
| 31 dic. 2015 | 10.97% | 20.85% | 130.39% | 24.71% | 16.53% | 97.70% | 24.97% | 21.66% | 9.94% | 10.75% | 17.40% | -59.19% | 31.74% |
| 31 dic. 2014 | 13.49% | 10.61% | 101.84% | 20.01% | 15.55% | 78.45% | 24.16% | 23.40% | 24.50% | 12.81% | 13.69% | -68.70% | 44.47% |
| 31 dic. 2013 | 16.91% | 10.23% | 91.90% | 23.00% | 26.57% | 27.05% | 8.17% | 18.68% | 8.85% | 28.83% | 21.74% | -32.81% | 53.62% |
| 31 dic. 2012 | 14.39% | 22.32% | 156.85% | 22.80% | 27.69% | 27.84% | 11.47% | 16.74% | 11.63% | 17.93% | 60.24% | -10.71% | 10.83% |
| 31 dic. 2011 | 23.25% | 19.35% | — | 19.35% | 32.11% | 41.60% | 8.06% | 16.94% | 11.50% | 12.18% | -45.65% | 3.76% | — |
| 31 dic. 2010 | 19.74% | 20.66% | — | 19.32% | 40.82% | 49.48% | 10.43% | 23.57% | 1.58% | 9.40% | -19.79% | -149.74% | — |
| 31 dic. 2009 | 71.49% | 25.14% | — | 20.32% | 45.45% | 41.40% | 8.36% | 24.25% | 21.85% | 9.59% | -17.10% | -58.57% | — |
| 31 dic. 2008 | 42.86% | 27.92% | — | 20.58% | -30.76% | 48.43% | 5.95% | 30.46% | 41.63% | 14.08% | -19.75% | -192.51% | — |
| 31 dic. 2007 | 20.50% | 20.28% | — | 17.72% | 21.61% | 46.69% | -67.62% | 24.41% | 18.01% | 12.53% | -22.94% | -144.23% | — |
| 31 dic. 2006 | 15.86% | 12.22% | — | 15.56% | 24.25% | -65.54% | 16.16% | 28.11% | 25.25% | 27.10% | -47.24% | -40.89% | — |
| 31 dic. 2005 | 26.77% | 23.39% | — | 17.96% | 18.34% | 26.88% | -28.79% | 27.49% | 25.85% | 12.32% | -83.72% | -85.05% | — |
Fuente: Bristol-Myers Squibb Co. (NYSE:BMY) | Return on Equity since 2005 (www.stock-analysis-on.net)
Comparación con el sector industrial: Farmacia y biotecnología
Bristol-Myers Squibb Co., ROE, tendencias a largo plazo, comparación con el sector industrial: farmacia y biotecnología
| Bristol-Myers Squibb Co. | Farmacia y biotecnología | |
|---|---|---|
| 31 dic. 2020 | -23.84% | — |
| 31 dic. 2019 | 6.66% | 29.60% |
| 31 dic. 2018 | 35.07% | 27.94% |
| 31 dic. 2017 | 8.58% | 14.50% |
| 31 dic. 2016 | 27.55% | 23.11% |
| 31 dic. 2015 | 10.97% | 22.96% |
| 31 dic. 2014 | 13.49% | 21.88% |
| 31 dic. 2013 | 16.91% | 20.86% |
| 31 dic. 2012 | 14.39% | 19.43% |
| 31 dic. 2011 | 23.25% | 16.36% |
| 31 dic. 2010 | 19.74% | 14.94% |
| 31 dic. 2009 | 71.49% | 21.95% |
| 31 dic. 2008 | 42.86% | 23.51% |
| 31 dic. 2007 | 20.50% | 18.18% |
| 31 dic. 2006 | 15.86% | 22.85% |
| 31 dic. 2005 | 26.77% | 19.61% |
Fuente: Bristol-Myers Squibb Co. (NYSE:BMY) | Return on Equity since 2005 (www.stock-analysis-on.net)
Comparación con la industria: Cuidado de la salud
Bristol-Myers Squibb Co., ROE, tendencias a largo plazo, comparación con la industria: cuidado de la salud
| Bristol-Myers Squibb Co. | Cuidado de la salud | |
|---|---|---|
| 31 dic. 2020 | -23.84% | — |
| 31 dic. 2019 | 6.66% | 23.37% |
| 31 dic. 2018 | 35.07% | 21.29% |
| 31 dic. 2017 | 8.58% | 13.56% |
| 31 dic. 2016 | 27.55% | 18.84% |
| 31 dic. 2015 | 10.97% | 18.48% |
| 31 dic. 2014 | 13.49% | 19.31% |
| 31 dic. 2013 | 16.91% | 18.98% |
| 31 dic. 2012 | 14.39% | 17.23% |
| 31 dic. 2011 | 23.25% | 15.96% |
| 31 dic. 2010 | 19.74% | 14.48% |
| 31 dic. 2009 | 71.49% | 19.23% |
| 31 dic. 2008 | 42.86% | 19.21% |
| 31 dic. 2007 | 20.50% | 16.90% |
| 31 dic. 2006 | 15.86% | 18.60% |
| 31 dic. 2005 | 26.77% | 19.18% |
Fuente: Bristol-Myers Squibb Co. (NYSE:BMY) | Return on Equity since 2005 (www.stock-analysis-on.net)